An executive Q&A from Labcorp Oncology underscored the growing operational and clinical importance of pairing germline and somatic testing in oncology. Rebecca Previs and Sarah Young discussed how integrated testing can improve biomarker-informed treatment selection and increase access to appropriate testing. The discussion also pointed to AI’s expanding role in genomics workflows, including how data from multiple sources can be interpreted more efficiently. While the segment is positioned as industry-focused rather than a specific trial readout, it reflects how testing strategies are being reorganized around precision oncology needs. For developers and clinicians, the message is that comprehensive genomic assessment is becoming a standard expectation, not an optional add-on.